NEW YORK. Aug. 24 – DNAPrint Genomics and scientific developer Pharsight have entered into a collaboration to empower DNAPrint’s pharmacogenomic product development, the company announced on Friday.
The terms of the contract, which is open-ended, call for Mountain View, Calif.-based Pharsight to provide DNAPrint with clinically phenotyped DNA specimens from patients who are taking medications known to elicit variable efficacy.
According to Tony Frudakis, DNAPrint’s CEO, the alliance hopes to reveal drug-reaction traits in patients diagnosed with “general metabolic disorders.”
Further details of the contract were not disclosed.
The collaboration will increase DNAPrint’s specimen database “by about 10 percent” and opens the door for similar deals between the companies, the Sarasota, Fla.-based research firm said in a statement.
Last month, DNAPrint joined forces with a small Malaysian biotech company to tap into government science grants for pharmacogenomic research in that country.
As GenomeWeb reported, terms of that collaboration called for DNAPrint to join DNAPro to establish DNAPrint Genomics Malaysia. DNAPrint is to own 49 percent of the company, while DNAPro will own 51 percent. The new company will apply for grants from the Malaysian Ministry of Science and Technology, Frudakis said at the time.